Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H34O5 |
Molecular Weight | 402.5238 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])C(=O)C[C@]4([H])CC(=O)CC[C@]4(C)[C@@]3([H])CC(=O)[C@]12C)[C@H](C)CCC(O)=O
InChI
InChIKey=OHXPGWPVLFPUSM-KLRNGDHRSA-N
InChI=1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1
Molecular Formula | C24H34O5 |
Molecular Weight | 402.5238 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6620121http://www.drugs.com/dict/dehydrocholic-acid.htmlCurator's Comment: description was created based on several sources, including http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/5935948
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6620121http://www.drugs.com/dict/dehydrocholic-acid.html
Curator's Comment: description was created based on several sources, including http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/5935948
Dehydrocholic acid is manufactured from cholic acid by oxidation. The main use of dehydrocholic acid is as a digestive aid in the dietary supplement industry. It is typically formulated with enzymes like papain and pancreatin. It has a stimulating effect on the secretion of bile by the liver (choleretic); improves absorption of essential food materials in states associated with deficient bile formation.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6877542
Curator's Comment: In rats, sodium dehydrocholate disrupts the blood-brain barrier for a period of over 3 days.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Anionic polypeptide fraction (APF) secretion in bile Sources: https://www.ncbi.nlm.nih.gov/pubmed/1502488 |
|||
Target ID: GO:0032782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2340963 |
|||
Target ID: CHEMBL2714 |
|||
Target ID: Q99626 Gene ID: 1045.0 Gene Symbol: CDX2 Target Organism: Homo sapiens (Human) |
|||
Target ID: map04976 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2340963 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Decholinum Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 3 times / day multiple, oral Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, 36-75 n = 11 Health Status: unhealthy Condition: recurrent acute cholangitis Age Group: 36-75 Sex: M+F Population Size: 11 Sources: |
Other AEs: Nausea, Diarrhea... Other AEs: Nausea (1 patient) Sources: Diarrhea (1 patient) Weight loss (1 patient) Pain in hand (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 1 patient | 250 mg 3 times / day multiple, oral Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, 36-75 n = 11 Health Status: unhealthy Condition: recurrent acute cholangitis Age Group: 36-75 Sex: M+F Population Size: 11 Sources: |
Nausea | 1 patient | 250 mg 3 times / day multiple, oral Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, 36-75 n = 11 Health Status: unhealthy Condition: recurrent acute cholangitis Age Group: 36-75 Sex: M+F Population Size: 11 Sources: |
Pain in hand | 1 patient | 250 mg 3 times / day multiple, oral Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, 36-75 n = 11 Health Status: unhealthy Condition: recurrent acute cholangitis Age Group: 36-75 Sex: M+F Population Size: 11 Sources: |
Weight loss | 1 patient | 250 mg 3 times / day multiple, oral Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, 36-75 n = 11 Health Status: unhealthy Condition: recurrent acute cholangitis Age Group: 36-75 Sex: M+F Population Size: 11 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Influence of dehydrocholate sodium on the biliary reabsorption of sulfobromophtalein sodium from the rat biliary tree after retrograde intrabilary injection. | 1976 Aug 15 |
|
Effects of sodium ursodeoxycholate, hyodeoxycholate and dehydrocholate on cholesterol and bile acid metabolism in rats. | 1983 May |
|
Anodic electrochemical oxidation of cholic acid. | 2001 Feb |
|
Choledocholithiasis in an infant of extremely low birthweight. | 2002 Apr |
|
Choleretic activity and biliary elimination of lipids and bile acids induced by an artichoke leaf extract in rats. | 2002 Dec |
|
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails. | 2002 Jun 17 |
|
Spasmocanulase in irritable bowel syndrome. | 2002 Sep |
|
Sterol-derived hormone(s) controls entry into diapause in Caenorhabditis elegans by consecutive activation of DAF-12 and DAF-16. | 2004 Oct |
|
Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. | 2004 Sep 8 |
|
Magnetic resonance cholangiopancreatography: potential usefulness of dehydrocholic acid (DHCA) administration in the evaluation of biliary disease. | 2008 Mar-Apr |
|
Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. | 2009 Aug 15 |
|
Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes. | 2010 Jul |
|
Surgical outcome in relation to duct size at the porta hepatis and the use of cholagogues in patients with biliary atresia. | 2010 Jul-Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/957600
in rats: intravenously as a constant infusion (3.1 mumol/min/kg body weight) or as a bolus injection (24.8 mumol/rat)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4254627
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:01:10 GMT 2023
by
admin
on
Sat Dec 16 17:01:10 GMT 2023
|
Record UNII |
NH5000009I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66913
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
157
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL514446
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
8796
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
C76605
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
D003685
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
NH5000009I
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
137881
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
DTXSID2022888
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
31459
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
42625
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
6674
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
SUB06945MIG
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
DEHYDROCHOLIC ACID
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
3141
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
m4142
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
201-335-7
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
DB11622
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
100000083477
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
1166502
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
81-23-2
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY | |||
|
794
Created by
admin on Sat Dec 16 17:01:11 GMT 2023 , Edited by admin on Sat Dec 16 17:01:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |